1. Introduction {#s0005}
===============

Frontotemporal dementia (FTD[1](#fn0005){ref-type="fn"}) is one of the most common forms of early onset dementia, occurring with similar frequency to Alzheimer\'s Disease (AD) in people under the age of 65 ([@bb0190]). This heterogeneous disorder most often presents with combinations of personality changes such as apathy, loss of empathy, and disinhibition (behavioral variant -- bvFTD) ([@bb0230]) or language deficits (primary progressive aphasia -- PPA). PPA is further divided into three variants - semantic (svPPA), nonfluent (nfvPPA) and logopenic (lvPPA) ([@bb0080]). The pathology underlying frontotemporal lobar degeneration is equally heterogeneous and involves abnormal accumulation of proteins including microtubule-associated protein tau, transactive response DNA-binding protein with molecular weight 43 kDa (TDP-43), and fused in sarcoma (FUS) protein, while the lvPPA clinical syndrome is most commonly associated with AD pathology ([@bb0220]).

The diagnosis of FTD currently poses a significant challenge for clinicians as the presenting symptoms overlap considerably with other diseases including primary psychiatric disorders and other dementias ([@bb0060]). This is especially true of bvFTD. Evidence suggests as many as 50% of people with bvFTD are initially diagnosed with a psychiatric disorder ([@bb0305]). As well, significant memory impairment can exist in bvFTD, comparable to that seen in AD ([@bb0010]; [@bb0135]).

The most common imaging method currently used in clinical practice is structural MRI, which is insufficiently sensitive for early stage diagnosis of FTD given that atrophy can be very subtle at the disease onset. Indeed, in a mixed neuropsychiatric population that is representative of clinical practice, a standard MRI with visual review had insufficient sensitivity (70%) to identify cases with bvFTD, while the usual alternative of \[18F\] FDG-PET had poor specificity (68%) ([@bb0270]). This can lead to erroneous or significantly delayed diagnosis, causing prolonged periods of uncertainty for patients and their families. The development of improved diagnostic biomarkers for the early detection of FTD is critical to ensure patients are getting the appropriate care as well as for the accurate identification of patients for clinical trials. Improving MRI methods is ideal given that MRI is already part of standard practice and there are currently no validated molecular biomarkers for FTD diagnosis. AD cerebral spinal fluid (CSF) and PET amyloid tracers can be used in the differential diagnosis of FTD from AD, as FTD will likely be negative for these ([@bb0155]), however FTD-specific CSF biomarkers or tau tracers are not available.

There has been considerable interest in automated morphometric analysis of MRI, most commonly assessing gray matter (GM) atrophy and, in recent years, white matter (WM) integrity using diffusion tensor imaging (DTI). Techniques such as voxel-based morphometry (VBM) and cortical thickness have demonstrated specific patterns of frontal and temporal GM atrophy on a group level ([@bb0155]). These patterns differ from those seen in other dementias (such as hippocampal atrophy found in AD). BvFTD is associated with atrophy primarily in the frontal lobe, insula, anterior cinguate cortex and basal ganglia ([@bb0155]; [@bb0195]; [@bb0250]). PPA is primarily associated with left-sided atrophy (language dominant hemisphere) in the initial disease stages; nfvPPA with inferior frontal and insular atrophy, svPPA with anterior temporal atrophy, and lvPPA with posterior temporal and parietal atrophy ([@bb0015]; [@bb0155]; [@bb0160]; [@bb0240]). WM changes have a more widespread distribution and likely precede GM atrophy ([@bb0120]; [@bb0130]; [@bb0155]).

A high discriminative power is needed to differentiate between diseases on an individual level, in order to be useful in clinical practice. However, with improving methods of morphometric analysis and the use of multivariate statistics and machine learning methods, it is becoming increasingly feasible to improve diagnosis at the individual level. An extensive body of literature exists classifying AD in this way. These studies have found overall high accuracy levels when comparing AD to controls (often \>90% accuracy) ([@bb0070]; [@bb0235]). In recent years several studies have attempted this type of classification for the diagnosis of FTD using a variety of MRI measures and machine learning algorithms.

The aim of this systematic review is to summarize the current literature studying the diagnostic classification of FTD utilizing morphometric MRI data on an individual level, with the aim of evaluating its potential usefulness and readiness for clinical practice.

2. Method {#s0010}
=========

This systematic review follows the recommendations of PRISMA ([@bb0140]; [@bb0170]) as applicable. An initial search was conducted up to March 12, 2018 using PubMed and PsychINFO with the following search terms: (frontotemporal dementia OR frontotemporal lobar degeneration) AND MRI AND ((diagnostic OR diagnosis) AND (accuracy OR classification OR prediction)). The search was limited to peer-reviewed, full text articles, published in English within the last 10 years (2007 or later) to focus on the most advanced image processing methods. All resulting papers were screened by title and abstract to exclude irrelevant studies, and full texts of selected articles were reviewed. Studies were included if they meet the following criteria: (1) conducted a diagnostic classification of FTD (behavioral or language variant, or both variants combined) versus controls or versus other disorders on an individual subject level and (2) used classification features derived from structural MRI, either alone or in combination. In the case of studies which conducted classifications based on MRI morphometry alone and in combination with other methods, only those results pertaining to MRI morphometry were included in this review. Reference lists of included articles were also manually searched to identify other relevant articles. The risk of bias and applicability of each included study was assessed with the QUADAS-2 tool ([@bb0280]).

3. Results {#s0015}
==========

The search produced 151 articles. Of these, 25 relevant articles were identified. Cross-reference list searches of each relevant article yielded three additional papers, resulting in a total of 28 papers for inclusion in this review ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1PRISMA flow chart of study selections.Fig. 1

3.1. Study characteristics {#s0020}
--------------------------

Eleven studies conducted a binary classification of FTD or specifically bvFTD from a control group. Seventeen studies conducted a binary classification of FTD or specifically bvFTD from AD. Six studies conducted a multi-class classification to differentiate FTD, AD and controls, while four studies conducted a multi-class classification between various dementia types and controls. Four studies conducted classifications of PPA; two studies differentiated PPA subtypes from each other and controls. One study classified PPA from controls. One study differentiated FTD subtypes (bvFTD and PPAs) from a combined group of all other subtypes and AD. Results are summarized in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}. Accuracy, sensitivity, specificity, and/or area under the receiver operating characteristic curve (AUC) are reported, if provided. In cases where raw numbers were reported, applicable performance measures were calculated from these numbers. In this paper we consider performance of 90% or greater as high, 70--90% as moderate, and \<70% as low.Table 1Classifications of bvFTD versus Controls or AD.Table 1bvFTDvs Controlsvs ADNameSampleClassificationMeasureROIsAccSSSPAUCAccSSSPAUC[@bb0030]27 bvFTDRandom forestCortical thicknessL inferior parietal Best 5 (L inferior parietal, R temporal pole, L isthmus cingulate, R inferior parietal, R precuneus)78768362 ADBest 5 (L inferior parietal, R temporal pole, L isthmus cingulate, R inferior parietal, R precuneus)828087DWIR uncinate; AD819643Best 5 (R uncinate; AD, RD, MD, FA, Genu of CC; FA)818961Combination5 CT + 5 WM tract827696Best 5 (L inferior parietal, R temporal pole, R precuneus, L isthmus cingulate, L superior parietal)847981[@bb0035]16 bvFTDLogistic regressionVolumesL medial middle frontal parenchymal8768.896.630 C[@bb0075]15 bvFTDLogistic regressionVolumecaudate79caudate + gyrus rectus GM8314 AD[@bb0130]27 bvFTDDTI-RDWhole-brain82800.820.6725 ADCorpus callosum93750.85L uncinate fasciculus82750.82L cingulum bundle74700.8320 CDTI-FAWhole-brain0.7378680.74L uncinate fasciculus77680.76L cingulum bundle63800.67Corpus callosum56800.73DTI-TDWhole-brain0.800.66DTI-ADWhole-brain0.740.59[@bb0165]52 bvFTDSVMVBM-GM densityWhole-brain81.778.984.6LOOCVFrontal lobe80.776.984.6Frontal + Basal ganglia & insula82.780.784.652 CTemporal lobe78.876.980.8Frontal & temporal lobe84.680.788.5Frontal + Temporal + Basal Ganglia & insula84.680.788.5[@bb0180]26 bvFTDSVMTraining Set LOOCVVBM-GM densityWhole-brain75628381698842 AD47 C25 bvFTDTest Set8560980.878264930.8142 AD47 C[@bb0215]30 bvFTDSVMLOOCVSurface displacementsL Hippocampus14830.48837620.492R Hippocampus43830.63150410.456L lateral ventricle79870.82660820.71234 ADR lateral ventricle64870.75563790.71414 CTrain/TestL Hippocampus50620.56250560.528R Hippocampus25750.5010.5L lateral ventricle100880.93875560.653R lateral ventricle751000.87562670.646[@bb0275]55 bvFTDNaïve BayesVBM-GM volumeAmygdale, hippocampus, MTL, temporal pole, DLPFC, VMPFC, striatum and insula51.436.466.754 AD10-fold CVTable 2Classifications of FTD vs Controls or AD.Table 2FTDvs Controlsvs ADNameSampleClassificationMeasureROIsAccSSSPAUCAccSSSPAUC[@bb0025]33 FTDSVMVBM-GM volumeWhole-brain0.950.7824 AD4-fold CVVBM-WM volume0.960.7634CVBM-Supratentorial brain volume0.950.72DTI-FAVBM-WM0.910.80volume + DTI-FA0.950.81[@bb0045]12 FTDSVMRAVENS-GM and WM volumePCA10084.337 ADLOOCV12 CFisher\'s discriminant AnalysisVolumeHippocampal, ventricular, total brain7570.9[@bb0055]19 FTDLogistic regressionVolumeFrontal8922 ADLOOCVParietal817923 CTemporal85Cortical thicknessFrontal88Parietal8282Temporal85[@bb0065]14 FTDSVMGMWhole-brain77.88021 ADLOOCVWMWhole-brain77.874.313CGMROI (a priori)85.260[@bb0095]19 FTDSVMGM volumeWhole brain89.294.783.318 ADLOOCV[@bb0100]12 FTDSVMVBM-GM volumeWhole-brain0.78122 ADSeparate test set[@bb0125]23 FTDSVMCortical ThicknessWhole-brain79.491.354.50.8717 AD2-level CV[@bb0145]38 FTDLogistic regressionGM densityPrecuneus82790.883Posterior cingulated87660.890Anterior temporal79690.79229 ADDTI-FACorpus callosum79590.795CombinationCorpus callosum, precuneus, posterior cingulated87830.938[@bb0150]72 FTDLinear regressionCortical thicknessData-driven89810.778Anatomical100540.80221 ADTrain/testVolumeGlobal GM651000.820Global ventricles100650.826DTI-FAData-driven100460.808Anatomical56780.649CombinationData-driven89890.874Anatomical78700.742[@bb0185]37 FTDRegressionVolumeHippocampus83808455555546 ADTrain/Test26 CTBMHippocampus, amygdala, posterior temporal lobe, lateral ventricle in frontal horn, central part and occipital horn, lateral ventricle in temporal horn, gyri hippocampalis et ambiens, anterior cingulate gyrus and superior frontal gyrus.829077626756VBM-GM concentration839177727667VBM-GM volume858982697166[@bb0285]14 FTDLogistic regressionGM volumeTemporoparietal cortex0.81Hippocampus0.74Temporoparietal cortex + hippocampus0.9314 AD[@bb0310]25 FTDLogistic regressionVBM-GM volumeROI1 (B frontotemporal, anterior callosal)65.780.148.70.66519 C4-fold CVROI2 (L temporal)63.977.046.60.722ROI3 (L dorsal frontal)45.774.25.40.566VBM-WM volumeROI159.277.234.60.627ROI258.171.536.40.657ROI347.479.85.30.606DTI-RDROI176.079.972.30.853ROI281.480.780.50.877ROI367.673.358.60.722Table 3Multi-class Classifications of FTD, AD, and Controls.Table 3FTD, AD and controlsNameSampleClassificationMeasureROIsAccSS (FTD)SP (FTD)AUC[@bb0025]33 FTDSVMVBM-GM volumeWhole-brain0.8524 AD4-fold CVVBM-WM volume0.8334 CVBM-Supratentorial brain volume0.84DTI-FA0.83VBM-WM volume + DTI-FA0.87[@bb0065]14 FTDSVMGMWhole-brain72.921 ADLOOCVWM66.713 CGMa priori ROIs56.3[@bb0115]18 FTDLinear discriminant analysisGM volumeWhole-brain parcellation76.3681.0866.67DWI-FA76.3672.9783.33DWI-RD89.0997.3072.22DWI-LD85.4589.1977.78Combination GM + DWI83.6491.8966.67LoCo87.2791.8977.7818 ADLOOCV19 C[@bb0175]30 bvFTDDiscriminant function analyses LOOCV1st analysis: VBM-GM volume, Subcortical volumes, DWI-FASignificant voxels/regions from paired group comparisons91.466.739 AD41 C2nd analysis: VBM-GM volume, subcortical volumes, DWI- AD, DWI-RD8675[@bb0215]30 bvFTDSVMVolumesL Hippocampus0.534 ADTrain/TestR Hippocampus0.54L lateral ventricle0.514 CR lateral ventricle0.5Laplacian invariantsL Hippocampus0.5R Hippocampus0.49L lateral ventricle0.5R lateral ventricle0.59Surface displacementsL Hippocampus0.66R Hippocampus0.56L lateral ventricle0.76R lateral ventricle0.77[@bb0275]55 bvFTDNaïve BayesVBM-GM volumeAmygdale, hippocampus, MTL, temporal pole, DLPFC, VMPFC, striatum and insula54.254 AD10-fold CV57 CTable 4Multi-class Classifications of Dementia.Table 4Multi dementia typesNameSampleClassificationMeasuresROIsAccSS (FTD)SP (FTD)AUC (FTD)[@bb0100]12 FTDSVMVBM-GM volumeWhole-brain0.78122 ADSeparate test cohort4 DLB18C[@bb0105]92 FTDDisease State Index (DSI)VolumesWhole-brain parcellation50.4VBM-GM concentration65.110-fold CVTBM64.3Manifold learningHippocampus and frontotemporal lobe50.4ROI-based grading58.3Vascular burden- WMH, cortical and lacunar infarcts volumes32.7223 ADAll features70.6629547 DLB24 VaD118 C[@bb0260]92 FTDRUSBoostVolumesWhole-brain parcellation58.666.67010-fold CVGradingCombination219 AD47 DLB24 VaD118 C[@bb0265]47 FTDDifferential-STANDGM densityWhole brain84.493.848 ADLOOCV20 DLB21 CTable 5PPA classifications.Table 5NameSampleClassificationMeasuresROIsAccSSSPAUCAccSSSPAUCAccSSSPAUCnfvPPA vs ControlslvPPA vs ControlssvPPA vs Controls[@bb0020]16 nfvPPASVMVBM-GM densityWhole-brain ROI (a priori from meta-analyses)9188940.9495911000.9597941000.978481880.908282820.91100100100117 svPPALOOCV11 lvPPA20 C[@bb0300]32 nfvPPASVMGM volumePCA89.187.590.60.9411001001001100100100138 svPPA2-level CV16 lvPPA115 C  svPPA vs nfvPPAlvPPA vs svPPAlvPPA vs nfvPPA[@bb0020]16 nfvPPASVMVBM-GM densityWhole-brain ROI (a priori from meta-analyses)7881750.8895100910.935564450.5917 svPPALOOCV7881750.8795100910.916473550.6411 lvPPA20 C[@bb0300]32 nfvPPSVMGM volumePCA89.184.493.80.96493.893.893.80.98481.381.381.30.87938 svPP2-level CV16 lvPPA115 C  PPA (svPPA and nfvPPA) vs Controls*AccSSSP*[@bb0035]14 PPALogistic regressionVolumesL anterior temporal90.978.696.730 C  bvFTD vs otherssvPPA vs. othersnfvPPA vs others*AccSSSPAccSSSPAccSSSP*[@bb0255]11 bvFTDSVMVBM-GM volumeA priori based on the NDH72.545.482.792.55097.582.5094.24 svPPALOOCV5 nfvPPA20 AD

Studies varied considerably in methodology. The majority of studies looked at changes in GM structure, most commonly using VBM to assess either GM concentration or volume. WM integrity was commonly assessed using DTI measures. Studies used a variety of whole-brain and region of interest (ROI) based approaches, including a priori selection of ROIs and the use of ROIs that showed significant differences in group-level comparison. Studies also varied widely in classification methods. Machine learning classification techniques were utilized by most studies, the most common being support vector machines (SVM). Most studies used a k-fold cross validation (CV) approach, most commonly with a leave-one-out CV strategy. Only one study used independent subject data (from a different cohort) in a separate testing set ([@bb0100]).

Almost all studies used a clinically defined diagnosis as the reference standard. Six studies ([@bb0035]; [@bb0075]; [@bb0130]; [@bb0165]; [@bb0185]; [@bb0275]) included a subset of patients with pathologically confirmed diagnosis or those with a known genetic mutation consistent with FTD. Three studies ([@bb0095]; [@bb0125]; [@bb0265]) used pathologically defined dementia diagnosis as the gold standard. Two studies ([@bb0150]; [@bb0145]) grouped subjects as AD or FTD based on the presence or absence of CSF biomarkers consistent with AD. Studies also varied considerably in disease severity. Studies report a variety of methods for evaluating disease severity (Mini Mental State Exam, Clinical Dementia Rating, disease duration) making comparison difficult. Four studies used a control group consisting in part or entirely of those with subjective cognitive decline ([@bb0065]; [@bb0105]; [@bb0180]; [@bb0260]). All others consisted of healthy, cognitively normal subjects. Studies also varied widely in their exclusion criteria. Some studies included FTD with concurrent motor symptoms while others excluded these subjects.

3.2. bvFTD vs Controls {#s0025}
----------------------

Five studies classified bvFTD from a control group ([@bb0035]; [@bb0130]; [@bb0165]; [@bb0180]; [@bb0215]) ([Table 1](#t0005){ref-type="table"} and [Fig. 2](#f0010){ref-type="fig"}a). In general studies could distinguish FTD from controls with moderate to high accuracy, although results are heterogeneous. Two studies measured GM concentration with VBM using a SVM classifier. [@bb0165] achieved highest accuracy, sensitivity and specificity when using a ROI approach (frontal and temporal lobes -- 84.6%, 80.7% and 88.5%, respectively), while [@bb0180] reported low sensitivity (60%) but high specificity (98%) with a whole-brain approach. [@bb0130] achieved moderate results using radial diffusivity from DTI. The highest result was reported by [@bb0215] using surface displacements of the left lateral ventricle as inputs to a SVM, using a train/test approach (AUC of 0.938, sensitivity of 100% and specificity of 88%) The result was somewhat lower when using leave-one-out CV (AUC of 0.826, sensitivity of 79, specificity of 87). These results contrast with this study\'s reported results for other regions (right lateral ventricle and left and right hippocampus) in which sensitivity is low. None of the studies classifying the bvFTD subtype from controls looked at different MRI metrics in combination.Fig. 2Visual representation of the classification accuracy for the different comparisons (for studies which conducted more than one classification, the best result is shown). a) behavioral variant frontotemporal dementia (bvFTD) vs Controls. b) Frontotemporal dementia (any subtype - FTD) vs Controls. c) bvFTD vs AD. d) FTD (any subtype) vs AD.Fig. 2

3.3. FTD vs controls {#s0030}
--------------------

Six studies classified a combined group of FTD clinical subtypes from a control group ([Table 2](#t0010){ref-type="table"} and [Fig. 2](#f0010){ref-type="fig"}b), again with overall moderate to high accuracy ([@bb0025]; [@bb0045]; [@bb0055]; [@bb0065]; [@bb0185]; [@bb0310]). [@bb0045] reported 100% accuracy when using GM and WM volumetric features derived from principle component analysis as inputs to an SVM, however this study was small (FTD n = 12) and may not have used a completely independent test set. Very high results were also reported by [@bb0025] when using GM, WM, or supratentorial brain volume with an SVM (AUC 0.95--0.96). This study did not report sensitivity and specificity numbers. In contrast, [@bb0310] reported poor results using GM or WM volumes and logistic regression in a ROI approach extracted from group differences, but achieved best results using radial diffusivity (accuracy, sensitivity, specificity, and AUC of 81.4%, 80.7%, 80.5%, 0.877, respectively). Two other studies reported moderately high results using various measures of GM structure alone (tensor-based morphometry, volumetry, VBM, cortical thickness) ([@bb0055]; [@bb0185]). Only one study ([@bb0025]) assessed a multimodal approach (WM volume and fractional anisotropy), which achieved a similar result to that by WM volume alone (AUC 0.95).

3.4. bvFTD vs AD {#s0035}
----------------

Six studies classified bvFTD from AD ([@bb0030]; [@bb0075]; [@bb0130]; [@bb0180]; [@bb0215]; [@bb0275]) ([Table 1](#t0005){ref-type="table"} and [Fig. 2](#f0010){ref-type="fig"}c). In general, results indicate that this is a much harder task than distinguishing from controls and results are highly variable. [@bb0030] achieved moderately high results using cortical thickness in a random forest approach to distinguish bvFTD from AD (accuracy, sensitivity, and specificity of 82%, 80%, and 87% respectively). These results were not majorly improved when combined with DTI measures. No other study looked at the accuracy of combined MRI metrics. Other studies reported low to moderate accuracy in classifying bvFTD from AD using a range of single metrics including DTI, GM concentration, volumetry, and surface displacements ([@bb0075]; [@bb0130]; [@bb0180]; [@bb0215]; [@bb0275]).

3.5. FTD vs AD {#s0040}
--------------

Eleven studies classified FTD (combined clinical subtypes, pathological subtypes, or CSF-defined) from AD ([@bb0025]; [@bb0045]; [@bb0055]; [@bb0065]; [@bb0100]; [@bb0095]; [@bb0125]; [@bb0150]; [@bb0145]; [@bb0185]; [@bb0285]) ([Table 2](#t0010){ref-type="table"} and [Fig. 2](#f0010){ref-type="fig"}d). Again, results are highly variable. [@bb0145] reported highest accuracy when using a combination of GM density and fractional anisotropy (sensitivity, specificity and AUC of 87%, 83%, and 0.938 respectively) when distinguishing CSF-defined FTD and AD using regression, although this study did not use an independent testing set. [@bb0150] also reported moderately high sensitivity, specificity and AUC (89%, 89%, and 0.874 respectively) to classify CSF-defined FTD and AD when using a combination of cortical thickness and fractional anisotropy in a data-driven approach. In contrast [@bb0095] reported similar numbers using GM volume alone, in a whole-brain approach with an SVM (accuracy, sensitivity, and specificity of 89.2%, 94.7%, and 83.3% respectively), while [@bb0285] reported high AUC (0.93) using GM volumes of the temporoparietal cortex and hippocampus. Other studies again reported low to moderate accuracy in classifying FTD from AD with a range of different metrics ([@bb0025]; [@bb0045]; [@bb0055]; [@bb0065]; [@bb0100]; [@bb0125]; [@bb0185]).

3.6. Multi-class classifications {#s0045}
--------------------------------

Several studies attempted a multi-class classification with varying accuracy. Six studies included a three-way classification between FTD, AD, and controls ([@bb0025]; [@bb0065]; [@bb0115]; [@bb0175]; [@bb0215]; [@bb0275]) ([Table 3](#t0015){ref-type="table"}). [@bb0115] reported the highest accuracy using radial diffusivity, with accuracy and sensitivity of 89.09% and 97.3% but lower specificity (72.22%) using linear discriminant analysis. Results were similar using the LoCo metric, a measurement of the amount of structural network disruption incurred by a GM region for a particular pattern of WM integrity loss (accuracy, sensitivity, and specificity of 87.27%, 91.89%, 77.78% respectively). Four studies conducted a multi-class classification between various dementias and controls ([@bb0100]; [@bb0105]; [@bb0260]; [@bb0265]) ([Table 4](#t0020){ref-type="table"}). [@bb0265] reported moderate sensitivity (84.4%) and high specificity (93.8%) for FTD classification versus all others using whole brain GM density approach and a novel classification approach (referred to as differential-STAND), however they did not have a completely independent test set. Results were considerably lower for other studies ([@bb0100]; [@bb0105]; [@bb0260]).

3.7. PPA subtypes {#s0050}
-----------------

Four studies included classifications of PPA ([@bb0020]; [@bb0035]; [@bb0255]; [@bb0300]) ([Table 5](#t0025){ref-type="table"}). Two studies classified each PPA subtype against controls using SVM of GM atrophy, with moderate to high accuracy across studies (accuracy ranged from 84 to 100%) ([@bb0020]; [@bb0300]). Both studies also classified subtypes against each other, with varying results. [@bb0300] reported highest accuracy, sensitivity, and specificity (89.1%, 84.4%, 93.8% respectively, AUC of 0.964) to distinguish svPPA from nfvPPA using GM volume and a principal component analysis approach. Results were very high for both studies for lvPPA vs svPPA, while [@bb0300] achieved highest results for lvPPA vs nfvPPA (accuracy, sensitivity, specificity, AUC of 81.3%, 81.3%, 81.3% and 0.879 respectively). [@bb0255] classified each FTD subtype against a group of all others and AD using GM volume and SVM, resulting in high specificity (97.5% and 94.2%) but very poor sensitivity (50% and 0%) for both svPPA and nfvPPA vs others, while [@bb0035] combined svPPA and nfvPPA subtypes together in a classification from a control group, achieving moderate sensitivity (78.6%) and high specificity (96.7%).

3.8. Risk of bias assessment {#s0055}
----------------------------

The results of the QUADAS-2 evaluation are given in [Table 6](#t0030){ref-type="table"}. The patient selection domain was rated as high risk of bias in six studies that had inappropriate exclusion criteria (e.g. exclusion of subjects with abnormalities on structural MRI other than atrophy, such as WM hyperintensities) combined with a case-control design. The index test was rated as high risk of bias in eight studies which did not use separate testing data or used all data to perform ROI selection or dimensionality reduction prior to classification. Two studies were given an unclear risk of bias on this domain. One study was rated as having applicability concerns on the index test domain as it only looked at the overall accuracy of multi-class classification of dementia types.Table 6QUADAS-2 Evaluation.Table 6StudyRisk of BiasApplicability concernsPatient selectionIndex testReference standardFlow and timingPatient selectionIndex testReference standard[@bb0020]LowLowLowLowLowLowLow[@bb0025]LowLowLowLowLowLowLow[@bb0030]HighLowLowLowLowLowLow[@bb0035]LowHighLowLowLowLowLow[@bb0045]LowUnclearLowLowLowLowLow[@bb0055]LowLowLowLowLowLowLow[@bb0065]HighLowLowLowLowLowLow[@bb0075]LowHighLowLowLowLowLow[@bb0090], [@bb0095]LowLowLowLowLowLowLow[@bb0100]LowLowLowLowLowLowLow[@bb0105]LowLowLowLowLowLowLow[@bb0115]LowLowLowLowLowLowLow[@bb0125]LowLowLowLowLowLowLow[@bb0130]LowHighLowLowLowLowLow[@bb0145]LowHighLowLowLowLowLow[@bb0150]LowLowLowLowLowLowLow[@bb0165]LowLowLowLowLowLowLow[@bb0175]HighHighLowLowLowLowLow[@bb0180]LowLowLowLowLowLowLow[@bb0185]HighUnclearLowLowLowLowLow[@bb0215]LowLowLowLowLowLowLow[@bb0255]HighLowLowLowLowLowLow[@bb0260]LowLowLowLowLowHighLow[@bb0265]LowHighLowLowLowLowLow[@bb0275]LowLowLowLowLowLowLow[@bb0285]LowHighLowLowLowLowLow[@bb0300]LowLowLowLowLowLowLow[@bb0310]HighHighLowLowLowLowLow

4. Discussion {#s0060}
=============

This systematic review provides a summary of studies attempting to classify FTD from non-FTD via morphometric MRI data with the aim to determine its potential for use as a diagnostic aide in clinical practice. Studies included in this review are highly heterogeneous in terms of subject selection, MRI methodology and classification methods, complicating the comparison of accuracy of results. However, overall studies report good levels of accuracy (see [Table 7](#t0035){ref-type="table"} for a summary of the best performance for each classification), indicating the potential value of MRI morphometry in the diagnosis of FTD.Table 7Summary of studies with the best performance.Table 7NameSampleClassificationMeasuresROIsAccSSSPAUCbvFTD vs Controls[@bb0215]30 bvFTDSVMSurface displacementsL lateral ventricle100880.93814 CTrain/testbvFTD vs AD[@bb0030]27 bvFTDRandom forestCortical thicknessBest 5 (L inferior parietal, R temporal pole, L isthmus cingulate, R inferior parietal, R precuneus)82808762 ADFTD vs Controls[@bb0045]12 FTDSVMRAVENS-GM and WM volumePCA10012 CLOOCVFTD vs AD[@bb0150]72 FTDLinear regressionCombination (Cortical thickness & DTI-FA)Data-driven89890.87421 ADTrain/testFTD vs AD & Controls[@bb0115]18 FTDLinear discriminant analysisDWI-RDWhole-brain parcellation89.0997.3072.2218 ADLOOCV19 CFTD vs other dementias[@bb0265]7 FTDDifferential-STANDGM densityWhole-brain84.493.8LOOCV48 AD20 DLB21 C4nfvPPA vs Controls[@bb0020]6 nfvPPASVMVBM-GM densityWhole-brain9188940.9420 CLOOCVlvPPA vs Controls[@bb0300]16 lvPPASVMGM volumePCA1001001001115 C2-level CVsvPPA vs Controls[@bb0020]17 svPPASVMVBM-GM densityROI (a priori from meta-analyses)100100100120 CLOOCV[@bb0300]38 svPPASVMGM volumePCA1001001001115 C2-level CVsvPPA vs nfvPPA[@bb0300]32 nfvPPASVMGM volumePCA89.184.493.80.96438 svPPA2-level CVlvPPA vs svPPA[@bb0020]11 lvPPASVMVBM-GM densityWhole-brain95100910.9317 svPPALOOCVlvPPA vs nfvPPA[@bb0300]32 nfvPPASVMGM volumePCA81.381.381.30.87916 lvPPA2-level CV

FTD could be diagnosed with high accuracy from control groups, with many studies finding accuracies of over 80% or 90% with good sensitivity and specificity. However, most studies include subjects with well characterized patients in which there is significant atrophy, and therefore the added benefit of morphometry is uncertain. Results distinguishing FTD from AD were somewhat poorer. This is unsurprising given that minimal atrophy is expected in control subjects and that there exists overlap in atrophy patterns between FTD and AD ([@bb0050]). Studies which conducted multi-class classifications did not all report specific sensitivity and specificity values for FTD, although [@bb0265] reported good sensitivity and specificity (84.4% and 93.8%) in distinguishing FTD from other dementias. Only four studies specifically classified PPAs, generally with moderate to high accuracy. No studies attempted to distinguish bvFTD patients from those with psychiatric disorders, and these two disorders have been shown to be difficult to distinguish clinically ([@bb0305]). However, it is likely that this distinction will be similar to that of control subjects as no atrophy is expected in most psychiatric disorders other than severe and persistent mental illness, such as schizophrenia with chronic psychotropic treatment, that have been linked to subtle volume loss over time ([@bb0005]).

Most studies have looked at GM atrophy. Fewer studies have used DTI measures, proving mixed results but with some studies suggesting DTI may be more sensitive in the early stages of the disease ([@bb0115]; [@bb0310]). Most studies included in this review only looked at single MRI measures. Hypothetically a multimodal approach combining various MRI modalities such as GM structure and WM integrity should produce more accurate classification than a single modality, as these modalities should provide complimentary information about different aspects of the disease. This is supported by some studies ([@bb0150]; [@bb0145]) while others found no improvement when adding white matter to cortical metrics ([@bb0025]; [@bb0090]). These differences are likely due to differing patient groups and methodology.

This review focuses on morphometric MRI measures as the majority of studies in this area have focused on morphometry, however a few recent studies have looked at the added benefit of arterial spin labeling MRI or functional MRI ([@bb0025]; [@bb0255]). This may provide additional discriminative power and is feasible given that these are all MRI sequences that can be performed in the same session.

4.1. Comparison to visual MRI reading {#s0065}
-------------------------------------

Currently, FTD diagnosis is usually assisted via visual reading of MRI scans with or without semi-structured visual rating scales in clinical practice. It is therefore important that an effective MRI morphometry-based classification tool improves on current practices.

[@bb0090] found that radiologists with different levels of experience varied widely in their ability to distinguish pathologically defined FTD from AD on visual reading of MRI (ranges for accuracy, sensitivity, and specificity were 56.8--83.8%, 55.6--83.8%, and 57.9--90.0% respectively) and generally performed poorer than an SVM classifier of GM volume on the same cohort ([@bb0095]). Accuracy was positively correlated with the radiologist\'s level of experience. [@bb0105] reported much poorer results (overall accuracy of 46.6%, with a sensitivity of 50% for FTD versus others) when using a disease state index classifier on multiple visual rating scales in the multi-class classification of dementia types compared to their morphometric results. In a mixed neuropsychiatric population, visual reading of baseline MRIs by neuroradiologists using visual rating scales reported high specificity (93%) but only moderate sensitivity (70%) in distinguishing bvFTD from non-bvFTD, using clinical diagnosis at two-year follow-up as the gold standard ([@bb0270]).

In a cohort of pathologically defined dementia ([@bb0085]), unstructured visual assessment by experienced raters resulted in moderate sensitivity (82%) and high specificity (99%) in distinguishing FTD from controls, while moderate sensitivity (74%) and specificity (81%) was achieved when distinguishing FTD from AD. These results are comparable with many of the results obtained from morphometry studies. Semi-structured visual rating scales were found to provide comparatively high sensitivity and specificity in distinguishing FTD from controls (82% and 89% using the medial temporal lobe atrophy (MTA) scale, and 89% and 97% when using an SVM on the results of multiple visual rating scales). Visual rating scales resulted in moderate specificity (81% for an orbito-frontal scale, and 88% when using an SVM on the results of multiple visual rating scales) but low sensitivity (55% and 56%) when distinguishing FTD from AD.

Overall the results from visual radiologists\' review appear generally poorer than the best reported results from MRI morphometry studies, indicating the potential usefulness of automated MRI morphometry for improving diagnosis of FTD. However, it is not proven at this point if morphometry outperforms semi-structures visual rating scales ([@bb0040]; [@bb0085]). It is possible that morphometric approaches could improve diagnostic accuracy in settings where clinicians have less experience in identifying FTD neuroradiological features. ([@bb0090]).

4.2. Single-subject approach to structural MRI {#s0070}
----------------------------------------------

While there has been major improvement in automated structural MRI processing pipelines over the years, there remain significant methodological challenges to its application at the single-subject level. One of the main limitations to the clinical validity of such methods is the variability with regards to different sites, scanners and repeated image acquisitions. This variability leads to inconsistency in measurements that reduce the accuracy of diagnostic classifications based on subtle differences in atrophy or other morphometric measures ([@bb0210]). While a comparison of the performance of the different currently available processing pipelines is beyond the scope of this paper, the ideal MRI processing pipeline must perform robust registration and tissue contrast normalization to achieve precise cortical and subcortical segmentation across different scanners. It should further be able to perform intra-subject registration to measure subtle brain changes over time. Being able to compare subjects to a large database of healthy controls across ages, sex and education level is also of significant benefit ([@bb0210]).

4.3. Limitations {#s0075}
----------------

Studies included in this review are highly heterogeneous in terms of population demographics and methodology. These issues are similar to those regarding the diagnostic classification of AD ([@bb0070]; [@bb0235]).

Studies varied considerably on the subjects they included. Studies using small homogenous samples may result in the overfitting of data. A major issue with studies is the inclusion of well-characterized subjects that tend to be at a later disease stage and therefore may find higher accuracy because brain changes are more substantial and easier to differentiate. Ideally studies need to include patients in the earliest stages of the disease when diagnoses are ambiguous, such as the naturalistic symptom-based inclusion approach taken by the Late-Onset Frontal lobe study ([@bb0110]). Many studies grouped FTD clinical variants together in analysis. Others have indicated that this may lead to the language variants driving the classification resulting in higher performance ([@bb0180]). Several studies conducted a group-level analysis and then used the significant regions from this analysis in their classification. This will reduce the generalizability of the results as the regions used may likely be biased to the specific group of patients included in the study. For these reasons, results may be artificially high. Most studies utilized a cross-validation approach, where *k* subjects are sequentially left out of the training group, while others split the subjects into separate training and testing sets. Ideally studies should also validate classifiers on a separate independent cohort. It is likely that this would result in lower accuracy than the numbers reported in several of the studies reviewed here, given the methodology used.

Studies also differed in the metrics used to report results. Here we have reported the most common metrics across studies (accuracy, sensitivity, specificity, and AUC). Some studies did not report sensitivity/specificity but only accuracy or AUC. While useful, these metrics are not sufficient on their own. As only a small number of studies reported balanced accuracy those numbers are not reported here.

Studies included in this review focused predominantly on sporadic FTD. A significant proportion of FTD cases are monogenic in nature (i.e., they are caused by an autosomal-dominant genetic mutation). To our knowledge there have been no published studies of single-subject morphometric MRI classification in the presymptomatic or early symptomatic stages of monogenic FTD. Studies in this population would be of interest to identify biomarkers of the preclinical or early clinical stage that would be a great benefit for future disease-modifying clinical trials of FTD. In addition, it remains to be determined how accurate FTD MRI biomarkers developed with sporadic FTD cohorts would fare in a population of genetic FTD given their well-documented less typical atrophy patterns extending beyond frontal and anterior temporal areas ([@bb0245]; [@bb0295]; [@bb0290]).

Most importantly, few published studies have attempted to apply machine learning derived diagnostic classifiers to real-life clinical settings at the individual level. This is a crucial step given that clinical populations are more heterogenous than well-characterize cohorts from large-scale imaging studies. For instance, pre-existing brain changes (e.g., past cerebro-vascular accident) and co-morbidities (e.g., alcohol use disorder) are commonly seen in memory clinics but are often not represented by the training sets of these studies. Only one study identified in this review attempted to replicate the typical population of a memory clinic ([@bb0100]). Although this comes with significant challenges and lower accuracy than in the training set ([@bb0100]), it is an essential step before recommending the clinical use of these algorithms.

Limitations of this systematic review include the possibility of incomplete retrieval of relevant papers, however more than one search engine was used and reference lists of included papers were reviewed for additional relevant papers, so this should be minimal. As only published studies were included in this review there is the potential for publication bias. The main biases identified in the included studies were the exclusion of subjects with abnormalities other than atrophy on structural MRI and the lack of an independent testing set.

4.4. Future directions {#s0080}
----------------------

In order to translate morphometric tools for FTD in clinical practice, it will be crucial to validate the use of automated morphometric MRI methods in a naturalistic mixed neuropsychiatric population, such as the distinction of those presenting with FTD-like symptoms at baseline into those ultimately diagnosed with FTD versus those not. Future studies should validate MRI automated morphometry methods in a mixed cohort of early disease stage patients, using final diagnosis (and ideally when available proven pathology at autopsy) as a gold standard. Larger multi-site datasets will also be important to develop deep learning approaches for categorical diagnostic classification, disease course prediction and to build models that could predict pathological subtypes in vivo ([@bb0205]). Morphometry could also improve practice by identifying data-driven subtypes with clinically relevant differences in symptom profile or prognosis ([@bb0225]). The methodology needs to be feasible for use in clinical practice; a straight-forward process that is not time consuming and is easy to interpret is needed, and it needs to be applicable across scanner types and centers. This type of method may be especially helpful for those clinicians with less experience diagnosing FTD, such as community hospitals and primary care physicians that do not have easy access to specialty FTD clinics. In addition to leading to earlier diagnosis and improved prognosis clinically, morphometric biomarkers could potentially improve patient selection and reduce required sample sizes in clinical trials ([@bb0200]), which would accelerate drug discovery.

5. Conclusions {#s0085}
==============

Automated morphometric MRI has potential to improve the diagnosis and prognosis of early stage FTD in clinical practice. Current evidence provides good support for its ongoing development. The inclusion of 3D-T1 MRI sequences in clinical imaging protocols would facilitate the development of these tools, and eventually the integration of these methods in practice. However, more studies that use rigorous methodology and prospectively validate findings in independent real-life cohorts are needed before this method could be recommended in clinical practice.
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For FTD vs AD classifications, sensitivity is defined as the proportion of correctly classified FTD subjects and specificity as the proportion of correctly classified AD subjects.
